<DOC>
	<DOCNO>NCT00253149</DOCNO>
	<brief_summary>The purpose study evaluate effectiveness safety risperidone ( antipsychotic medication ) versus placebo add-on therapy mood stabilizer treatment manic episode associate bipolar disorder .</brief_summary>
	<brief_title>A Study Effectiveness Safety Risperidone add-on Therapy Mood Stabilizers Treatment Manic Episodes Associated With Bipolar Disorder</brief_title>
	<detailed_description>Risperidone , widely use treatment schizophrenia , show effective treatment manic mixed episode associate bipolar disorder . Antipsychotic drug like risperidone also use additional therapeutic agent treatment patient responsive mood stabilizer alone . This randomized , double-blind , placebo-controlled study evaluate effectiveness safety risperidone compare placebo , addition mood stabilize drug treatment patient experience manic episode . Treatment one group patient haloperidol use internal control trial . The study two phase : double-blind treatment phase ( 3 week ) open-label phase ( 10 week ) . During double-blind treatment phase patient receive risperidone , haloperidol , placebo tablet take day gradually increase dos ( adjust 1 6 mg/day risperidone 2 12 mg/day haloperidol ) , continue treatment mood stabilizer ( lithium valproate ) . In open-label phase patient receive risperidone dosage gradually adjust achieve optimal effectiveness ( dose range 0 6 mg/day ) ; phase patient continue therapy mood stabilizer ( lithium , valproate , , phase , carbamazepine ) . The primary measure effectiveness change Young Mania Rating Scale ( YMRS ) total score baseline end double-blind treatment . Additional assessment effectiveness include Brief Psychiatric Rating Scale ( BPRS ) ; Clinical Global Impression ( CGI ) , evaluate change severity disorder ; Hamilton Depression Rating Scale ( HAMD ) . Safety assessment include incidence adverse event throughout study ; measurement vital sign ( pulse blood pressure ) evaluation presence severity extrapyramidal symptom Extrapyramidal Symptom Rating Scale ( ESRS ) specify interval ; clinical laboratory test ( hematology , biochemistry , urinalysis ) study initiation , completion double-blind treatment , end study . The study hypothesis daily treatment risperidone add-on therapy provide good effectiveness placebo , measure Young Mania Rating Scale score , treatment manic phase bipolar disorder . Double-blind ( daily dos , take orally day ) - Days 1 2 : risperidone 2 mg , haloperidol 4 mg , placebo . Days 3 4 : risperidone 1 - 4 mg , haloperidol 2 - 8 mg , placebo . Days 5 - 21 : risperidone 1 - 6 mg , haloperidol 2 - 21 mg , placebo . Open-label : risperidone 0 - 6 mg/day 10 week .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Bipolar Disorder</mesh_term>
	<mesh_term>Risperidone</mesh_term>
	<criteria>Diagnosis Bipolar Disorder accord Diagnostic Statistical Manual Mental Diseases , 4th edition ( DSMIV ) hospitalize mania score &gt; =20 Young Mania Rating Scale ( YMRS ) ( patient concurrent symptom depression eligible ) inpatient minimum first 4 day doubleblind treatment therapy lithium valproate ( mood stabilizer ) start treatment study medication medically stable basis physical examination , medical history , electrocardiogram result . Other Axis I DSMIV diagnosis ( except nicotine caffeine dependence ) history alcohol drug abuse dependence within 4 week start study seizure disorder require medication know sensitivity risperidone , haloperidol , lithium , valproate carbamazepine pregnant nursing female , lack adequate contraception .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2011</verification_date>
	<keyword>risperidone</keyword>
	<keyword>antipsychotic agent</keyword>
	<keyword>bipolar disorder</keyword>
	<keyword>manic episode</keyword>
</DOC>